Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405,India.
Pharm Nanotechnol. 2021;9(5):308-316. doi: 10.2174/2211738509666211123091913.
Alzheimer's disease (AD) is a neurological disease that affects many of the world's rapidly ageing population. In the etiology of Alzheimer's disease (AD), the involvement of amyloid β (Aβ) plaque accumulation and oxidative stress in the brain have important roles. Various drugs have been proposed to prevent and treat AD, but delivering these therapeutic agents to the brain is difficult. Over the last decade, nanoparticle-mediated drug delivery represents one promising strategy to increase the CNS penetration of several therapeutic moieties successfully. Different nanocarriers are being investigated to treat and diagnose AD. NTDDS (nanotechnology-based drug delivery systems) can be used in various methods to improve patient compliance and treatment outcomes. However, literature analysis revealed that clinical activities, such as NTDDS application in Alzheimer's disease research lag behind despite extensive research. This review gives an account of the BBB and discusses the literature on some drugs, which are successfully encapsulated as nanoparticles for a future therapeutic approach. It also emphasizes the current clinical studies for Alzheimer's disease therapy.
阿尔茨海默病(AD)是一种影响世界上许多人口迅速老龄化的神经退行性疾病。在阿尔茨海默病(AD)的发病机制中,淀粉样β(Aβ)斑块积累和大脑中的氧化应激起着重要作用。已经提出了各种药物来预防和治疗 AD,但将这些治疗剂递送到大脑是很困难的。在过去的十年中,纳米颗粒介导的药物递送代表了一种很有前途的策略,可以成功地增加几种治疗剂在中枢神经系统中的穿透性。不同的纳米载体正在被研究用于治疗和诊断 AD。NTDDS(基于纳米技术的药物传递系统)可以用于多种方法来提高患者的依从性和治疗效果。然而,文献分析表明,尽管有广泛的研究,但 NTDDS 在阿尔茨海默病研究中的临床应用仍然滞后。本文综述了 BBB,并讨论了一些已成功封装为纳米颗粒的药物的文献,这些药物有望成为未来的治疗方法。它还强调了目前用于阿尔茨海默病治疗的临床研究。